The American Journal of Surgery
Volume 194, Issue 5 , Pages 606-610 , November 2007

Increasing incidence of methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: reconsideration of empiric antimicrobial therapy

Presented at the 31st Annual Surgical Symposium of the Association of VA Surgeons, Little Rock, AR, May 10–12, 2007

Received 25 May 2007 ,Revised 9 July 2007

References 

  1. Crum NF, Lee RU, Thornton SA, et al. Fifteen year study of the changing epidemiology of methicillin-resistant Staphylococcus aureus. Am J Med. 2006;119:943–951
  2. Public Health Dispatch: Outbreaks of Community-Associated Methicillin-Resistant Staphylococcus Aureus Skin Infections–Los Angeles County, California 2002–2003; Available at: www.cdc.gov. MMWR Weekly February 7, 2003/ 52(05);88.
  3. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care associated methicillin-resistant Staphylococcus aureus infection. JAMA. 2003;290:2976–2984
  4. Fagan SP, Berger DH, Rahwan K, et al. Spider bites presenting with methicillin-resistant Staphylococcus aureus soft tissue infection require early aggressive treatment. Surg Infect (Larchmt). 2004;5:321–322
  5. Kirst HA, Thompson DG, Nicas TI. Usage of vancomycin (in kilograms) in the United States, France, Italy, Germany, United Kingdom, and the Netherlands. Antimicrob Agents Chemother. 1998;42:1303–1304
  6. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol. 2006;44:3883–3886
  7. Kralovic SM, Danco LH, Roselle GA. Laboratory reporting of Staphylococcus aureus with reduced susceptibility to vancomycin in United States Department of Veterans Affairs Facilities. Emerg Infect Dis. 2002;8:402–407
  8. Rennie RP, Jones RN, Mutinick AH, et al. Occurrence and antimicrobial susceptibility patterns of pathogen isolated from skin and soft tissue infections: report from the SENTRY antimicrobial surveillance program (United States and Canada, 2000). Diagn Microbial Infect Dis. 2003;45:287–293
  9. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigacycline in the treatment of skin and skin-structure infections: results of 2 double blind phase 3. Clin Infect Dis. 2005;41(suppl 5):S341–S353
  10. Weber JT. Community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2005;41(suppl):S269–S272
  11. Kazakova SV, Hageman JC, Matava M, et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med. 2005;352:468–475
  12. Ito T, Katayama Y, Asada K. Structural comparison of three types of staphylococcal cassette chromosome mec integrated in the chromosome in methicillin-resistant Staphylococcus aureus in Australia. Antimicrob Agents Chemother. 2001;45:1323–1336
  13. King MD, Humphrey BJ, Wang YF. Emergence of community acquired methicillin-resistant staphylococcus aureus USA 300 Clone as the prdominant cause of skin and soft-tissue infections. Ann Intern Med. 2006;144:309–317
  14. Ruhe JJ, Smith N, Bradsher RW, Menon A. Staphylococcl aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis. 2007;44:777–784
  15. Frazee BW, Lynn J, Charlebois ED, et al. High prevalence of methicillin-resistant in emergency department skin and soft tissue infection. Ann Emerg Med. 2005;45:311–320
  16. Fiebelkorn KR, Crawford SA, McElmeel ML, et al. Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci. J Clin Microbiol. 2003;41:4740–4744
  17. Rybak MJ, LaPlante KL. Community-acquired methicillin-resistant Staphylococcus aureus: a review. Pharmacotherapy. 2005;25:74–85
  18. CDC. Staphylococcus aureus resistant to vancomycin. Available at: www.cdc.gov. MMRW Weekly July 5, 2002/ 51;565–7.
  19. CDC. Reduced susceptibility of Staphylococcus aureus to vancomycin–Japan, 1996. MMWR Morb Mortal Wkly Rep. 1997;46:624–4
  20. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin for methicillin-resistant Staphylococcus aureus infections. Arch Intern Med. 2006;166:2138–2144
  21. Howden BP, Ward PB, Charles PGP, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis. 2004;38:521–528
  22. Weigelt J, Itani K, Stevens D. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infection. Antimicrob Agents Chemother. 2004;188:760–766
  23. Martone WJ, Lamp KC. Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylooccus aureus: results from the core registry. Cur Med Res Opin. 2006;22:2337–2343
  24. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673–1681
  25. Fowler VG, Boucher HW, Corey R, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653–665
  26. Drew RH. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Pharmacotherapy. 2007;27:227–249

PII: S0002-9610(07)00643-5

doi: 10.1016/j.amjsurg.2007.07.016

The American Journal of Surgery
Volume 194, Issue 5 , Pages 606-610 , November 2007

Article Tools

* Image Usage & Resolution